This study was carried out to determine sero-prevalence of hepatitis B and hepatitis C virus co-infection among pregnant women. Viral hepatitis during pregnancy is associated with high risk of maternal complications; infections with Hepatitis B virus (HBV) or the Hepatitis C virus (HCV) are public health problems. Worldwide, there are about 350 million HBV carriers and 130 to 170 million people infected with HCV. The presence of HBV and HCV was determined using third-generation enzyme immunoassay (EIA), reactive samples were further confirmed using enzyme linked immune sorbent assay (ELISA) (Bio-Rad, France). Age group 26-30 and 31-35 had highest frequency of 240 (36.98%) and 206 (31.74%) respectively in HBV and HCV. Sero prevalence of HBV and HCV were 44 (6.78%) and 9 (1.39%) respectively. Prevalence of HBV and HCV co-infection was 1 (0.15%) in age group 31-35. Proper management of maternal hepatitis during the prenatal phase ensures better outcomes in the infant, therefore screening of pregnant women for hepatitis B and C virus are necessary in order to identify those neonates at risk of transmission.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.